Welcome! Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Please take a moment to confirm your subscription below so we can ensure these updates reach your inbox.
Confirm Your Subscription Here
The Earnings360 Team
Additional Reading from MarketBeat.com Why GRAIL Stock Could Be Biotech's Next Big BreakoutWritten by Bridget Bennett. Published 11/19/2025. 
Key Points - Insider buying is a reliable signal in market pullbacks, offering long-term confidence amid short-term volatility.
- Biotech stock GRAIL is one to watch, with its breakthrough cancer detection technology nearing FDA approval.
- Despite economic concerns, the American Dream is still attainable through long-term investing, saving, and strategic financial choices.
Retail investors are understandably on edge after several sessions of market volatility. But bestselling author and Oxford Club strategist Alexander Green, in his new book The American Dream, says we’re still in one of the best times in history to build wealth—especially if you think long-term and stick to time-tested principles. According to Green, this pullback isn’t as severe as it may feel. "Just last Wednesday, the Dow hit an all-time high," he noted, adding that recent selling has more to do with valuation concerns and interest-rate uncertainty than any fundamental breakdown. Why the Market Pulled Back Silver has already made one of the strongest moves in the commodities market this year, and demand from industries like EVs, aerospace, AI hardware, and solar continues to accelerate. With supply growth struggling to keep pace, this is the type of setup that historically leads to sharp, fast revaluations — long before the mainstream headlines catch on.
That's why we created a new Silver Wealth Guide outlining the forces driving this breakout, how industrial demand is reshaping the market, and the steps investors can consider before silver becomes the next front-page story. Get the Silver Forecast Now Green points to two main drivers. First, investors are reassessing elevated tech and AI valuations, particularly as earnings season puts those expectations under the microscope. Second, inflation readings and softer hiring data have reduced hopes that the Fed will cut rates in December. With the central bank emphasizing a "data-dependent" approach, markets are less confident relief is imminent. Why Selling Now Might Be the Wrong Move Rather than trying to predict where markets will head next week, Green encourages investors to zoom out. He calls himself "a long-term optimist" and notes that, historically, the market trends upward over time. Traders may want to be cautious in the short term, but long-term investors often find these dips are opportunities to buy high-quality stocks at more attractive prices. Insider Buying Can Point the Way One reliable signal in choppy markets is insider buying. Green suggests paying attention when officers and directors—people with access to non-public financial information—are putting their own money into their companies. He recommends tracking insider trading activity to see which stocks executives are buying, not just selling. While insiders aren’t infallible, their actions can be a useful signal when markets are in flux. A Biotech Breakout to Watch: GRAIL One sector Green is focused on right now is biotech, where artificial intelligence is helping accelerate drug development and reduce costs. He highlighted one company in particular: GRAIL (NASDAQ: GRAL). Spun off from Illumina, GRAIL developed the Galleri Test, which can detect more than 50 types of cancer from a simple blood draw. Green has used the test himself and says it felt reassuring to get a broad screening for cancers that often go undetected until late stages, such as pancreatic cancer. With FDA fast-track status and potential insurance reimbursement on the horizon, Green views GRAIL’s roughly $3 billion market cap as a starting point. The Biotech Risk—and Big Pharma's Appetite Biotech investing carries risk: most drug candidates never clear all three phases of clinical trials. Still, large pharmaceutical companies like Merck (NYSE: MRK), Pfizer (NYSE: PFE), and Bristol Myers (NYSE: BMY) actively acquire promising smaller firms to offset expiring patents and fill pipeline gaps. Green pointed to Johnson & Johnson (NYSE: JNJ) as a recent example: the company invested in a private firm developing a prostate cancer drug before it received FDA approval—underscoring how aggressive Big Pharma can be when clinical data looks promising. Green also argues biotech is particularly compelling because healthcare tends to be recession-resistant. People seek treatment regardless of the economic cycle, and for investors wanting to weather volatility, sectors such as healthcare, utilities, consumer staples, and food companies often offer steadier demand than high-flying AI names. The American Dream Is Still Possible—But Mindset Matters Despite economic headwinds, Green contends the American Dream is far from dead. He wrote The American Dream to counter the growing narrative that it’s out of reach. He was surprised to see polls showing nearly 70% of Americans believe it’s no longer attainable. The reality, he says, is that with low-cost investment tools, commission-free trading, and abundant information, building wealth has never been more accessible. The real challenge is knowing what to do—and having the discipline to stick with it. He breaks it down simply: if a 25-year-old invests $190 per month in an S&P 500 index fund, they could have $1 million by age 65—tax-free in a Roth IRA. No extreme frugality required. "You could eat out, take trips, and still build wealth," Green says—as long as you save consistently and leave that money to compound. Creative Solutions for Today's Housing Market Homeownership may feel out of reach, but Green says there are still paths in. Mortgage rates have risen and prices are higher than during the pandemic, but alternative approaches can help. He shares his personal story of buying two houses with no money down by working directly with motivated sellers and assuming their mortgages through a method sometimes called a "contract for deed." It might not get you the perfect home immediately, but it can help you start building equity sooner. Stay Focused on the Long Game Market volatility will come and go. What matters is how you respond. Whether it’s tracking insider moves, exploring high-upside sectors like biotech, or simply committing to regular saving and investing, Green’s message is clear: the American Dream remains within reach. Keep your eyes on it—and take the next right step.
| 
